Anika Therapeutics SG&A Expense (Quarterly) Analysis

Anika Therapeutics Inc (ANIK)

27.90 +0.31 (+1.12%) USD | NASDAQ | May 06, 16:00

27.90 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 1993. Upgrade now.

Date	Value
December 31, 2023	20.34M
September 30, 2023	24.83M
June 30, 2023	23.69M
March 31, 2023	27.00M
December 31, 2022	23.05M
September 30, 2022	21.28M
June 30, 2022	21.27M
March 31, 2022	19.20M
December 31, 2021	20.43M
September 30, 2021	17.50M
June 30, 2021	17.99M
March 31, 2021	18.18M
December 31, 2020	15.18M
September 30, 2020	15.90M
June 30, 2020	14.55M
March 31, 2020	14.43M
December 31, 2019	12.24M
September 30, 2019	7.539M
June 30, 2019	7.502M
March 31, 2019	7.672M
December 31, 2018	6.129M
September 30, 2018	5.70M
June 30, 2018	6.417M
March 31, 2018	16.09M
December 31, 2017	6.678M

Date	Value
September 30, 2017	4.823M
June 30, 2017	4.972M
March 31, 2017	5.067M
December 31, 2016	5.488M
September 30, 2016	4.28M
June 30, 2016	4.255M
March 31, 2016	3.99M
December 31, 2015	4.523M
September 30, 2015	3.309M
June 30, 2015	3.388M
March 31, 2015	3.605M
December 31, 2014	3.673M
September 30, 2014	4.044M
June 30, 2014	3.866M
March 31, 2014	3.491M
December 31, 2013	2.400M
September 30, 2013	3.189M
June 30, 2013	3.401M
March 31, 2013	3.947M
December 31, 2012	3.667M
September 30, 2012	3.602M
June 30, 2012	4.108M
March 31, 2012	3.351M
December 31, 2011	4.869M
September 30, 2011	4.712M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

7.502M

Minimum

Jun 2019

27.00M

Maximum

Mar 2023

18.00M

Average

18.18M

Median

Mar 2021

SG&A Expense (Quarterly) Benchmarks